See the pattern, not just the headline.

Enveda raises $311 million to advance AI-discovered medicines and scale its platform

Enveda closed a $311 million Series E financing led by Catalio Capital Management. The company said proceeds will advance three clinical-stage medicines into later development, bring additional inflammatory and metabolic programs into clinical trials and scale its AI-native drug-discovery platform.